The Latest Breaking News from Multiple Sclerosis

People living with multiple sclerosis join growing chorus for reforms to 'clearly broken' NDIS

People living with multiple sclerosis are joining calls for urgent reforms to the "broken" NDIS system that's left many with either not enough funding or none at all amid a lack of awareness of their neurological condition.

ABC News · Aug 30, 2022

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga · Aug 15, 2022

Eilish McColgan’s golden template falls short in European 10,000m

The British 400m runner Laviai Nielsen revealed she has multiple sclerosis while Germany’s Richard Ringer won the marathon with sprint finish

The Guardian - UK · Aug 15, 2022

Scots mum's memory loss and confusion after holiday turned out to be chronic illness triggered by heat

Weeks after returning to Scotland from Morocco, Linda Hoskins was diagnosed with Multiple Sclerosis (MS).

Daily Record · Jul 19, 2022

Almost 600 patients diagnosed with multiple sclerosis in 2021

ALMOST 600 patients were diagnosed with multiple sclerosis (MS) in Scotland in 2021.

The National (Scotland) · Jul 19, 2022

Briton finishes epic US cycle ride for multiple sclerosis fundraising

Antony Butcher reaches San Francisco after pedalling 4,000 miles from New York and raising £25,000

The Guardian - UK · Jul 14, 2022

Why Sanofi Shares Are Falling Today

The FDA has placed Sanofi SA's (NASDAQ:SNY) Phase 3 studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold.  New enrollment in the U.S. is paused, and participants in the U.S. who have been in the trial for fewer than 60 days shall suspend the study drug.  The participants who…

Benzinga · Jun 30, 2022

Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with multiple sclerosis (MS).

Benzinga · Jun 28, 2022

Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced topline results from the Phase 3 RELEASE MSS1 trial of nabiximols oromucosal spray on clinical measures of spasticity in multiple sclerosis.  The trial did not meet the primary endpoint of change in Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21. Nabiximols oromucosal spray is a complex…

Benzinga · Jun 28, 2022

Ray Of Hope: Protein Study Could Pave Way For New Multiple Sclerosis Therapy

"Our results are a window of opportunity for new research strategies of demyelinating diseases such as MS."

Zenger · Jun 22, 2022